FY2025 EPS Estimate for Organigram Global Lowered by Analyst

Key Points

• Analysts at Atb Cap Markets have lowered their FY2025 EPS estimate for Organigram Global from $0.07 to $0.05, while the current consensus estimate stands at ($0.19) per share.
• Wall Street Zen has downgraded Organigram Global’s stock from a "hold" rating to a "sell" rating.
• In its most recent quarterly earnings report, Organigram Global reported an EPS of ($0.03), missing analyst expectations and generating revenue of $50.49 million compared to estimates of $68.04 million.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Equities research analysts at Atb Cap Markets cut their FY2025 EPS estimates for shares of Organigram Global in a report released on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings of $0.05 per share for the year, down from their previous estimate of $0.07. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share. Atb Cap Markets also issued estimates for Organigram Global's FY2027 earnings at $0.04 EPS.

Separately, Wall Street Zen cut shares of Organigram Global from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th.

Organigram Global Price Performance

Shares of NASDAQ:OGI traded up $0.03 during mid-day trading on Monday, reaching $1.60. 894,643 shares of the company were exchanged, compared to its average volume of 938,733. The firm has a market cap of $214.48 million, a price-to-earnings ratio of 32.01 and a beta of 1.45. The firm's 50-day simple moving average is $1.44 and its 200 day simple moving average is $1.27. Organigram Global has a 1 year low of $0.85 and a 1 year high of $2.05.

Organigram Global (NASDAQ:OGI - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). The company had revenue of $50.49 million for the quarter, compared to analysts' expectations of $68.04 million. Organigram Global had a negative return on equity of 8.19% and a net margin of 2.86%.

Institutional Investors Weigh In On Organigram Global

Large investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC purchased a new stake in Organigram Global during the 4th quarter worth about $26,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Organigram Global during the 1st quarter worth about $30,000. Oxford Asset Management LLP purchased a new stake in Organigram Global during the 4th quarter worth about $50,000. Cidel Asset Management Inc. increased its holdings in Organigram Global by 112.3% during the 2nd quarter. Cidel Asset Management Inc. now owns 37,103 shares of the company's stock worth $50,000 after purchasing an additional 19,627 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new stake in Organigram Global during the 2nd quarter worth about $54,000. 34.63% of the stock is owned by hedge funds and other institutional investors.

About Organigram Global

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.